The Nuts & Bolts of Due Diligence in Biopharma Partnering

Learn about the most important aspects to consider during the due diligence process leading up to a successful partnership.

The topics covered in this whitepaper include:

  • The importance of IP due diligence

  • What large Pharma expects when entering due diligence with a biopharma company

  • Best ways to present and stage the information that you disclose to a potential partner

  • Best practices for the best long-term partnerships


By supplying my contact information, I authorize ShareVault to contact me about relevant content, products, and services. We're committed to your privacy, for more information, check out our Privacy Policy.


Company team

Linda Pullan, PhD

Pullan Consulting

Linda offers biotech and
pharmaceutical companies consulting
in all aspects of partnering. Linda has
a Ph.D. in Biochemistry, a B.S. in
Chemistry, and more than twenty
years of drug industry
experience. Learn More

Company team

James A. McCarthy, CLP, MBA

Corporate and Business Development, Alliance Management, CorpDev Ventures 

Jim has 30 years of life sciences professional experiences with projects and deals in over 30 countries with over 80 completed agreements across a range of transactions valued in excess of $900 million. His background includes a twenty-five year career with Bristol-Myers Squibb and Eli Lilly & Company and over fifteen years in international corporate business development and licensing roles.

Company team

Natalie Mirutenko, PhD

Transaction and Due Diligence Senior Director for the Center of External Innovation at Takeda

Natalie is an accomplished biopharmaceutical Business Development professional with a strong track record of results oriented achievements in technology, company, and product licensing and acquisition. She has over 35 years of diversified biopharmaceutical experience, with scientific, financial, strategic, and business perspective.

Company team

David L. Snitman, PhD

Partner, DL Snitman Inc and Former COO, Array BioPharma

David is a partner in a biotech business development-consulting agency, DL Snitman Inc. He is a Cofounder of Array BioPharma and lead over a dozen partnering deals, providing more then $600 M in non-dilutive capital. 

Company team

Patrick Gattari, JD

Partner, McDonnell Boehnen Hulbert & Berghoff

Patrick's practice focuses on patent prosecution and technology licensing, with emphasis in biotechnology, pharmaceuticals, diagnostics, and medical devices. His 20-plus years of practice has emphasized patent portfolio management and the licensing, acquisition, and sale of intellectual property. Learn More

Company team

Ann-Marie Costelloe, AFBPS

Psychologist | Executive Consultant, Somerville Partners

With over 20 years of organizational development consulting with organizations, teams and individuals, Ann-Marie directly contributes to financial success by customizing solutions to help leaders increase employee engagement and contributions, align strategy and tactics, and elevate performance across the business. Learn More 

Company team

William Gangi, MS, MBA

Director, Due Diligence Program Manager - Corporate Development, Shire

William currently serves as a Director, Due Diligence Program Manager within the Corporate Development department at Shire. He has 20 years of drug development, commercialization and strategic operations experience within the biopharmaceutical industry.

vdr for life sciences or biopharma

sharevault free trial or biopharma

sharevault demo or biopharma